The use of O-(2-[ 18 F]fluoroethyl)-l-tyrosine ([ 18 F]FET) as a positron emission tomography (PET) tracer for brain tumor imaging might have some limitations because of the relatively low affinity for the L-type amino acid transporter 1 (LAT1). To assess the stereospecificity and evaluate the influence of aromatic ring modification of phenylalanine LAT1 targeting tracers, six different fluoroalkylated phenylalanine analogues were synthesized. After in vitro K i determination, the most promising compound, 2-[ 18 F]-2fluoroethyl-l-phenylalanine (2-[ 18 F]FELP), was selected for further evaluation and in vitro comparison with [ 18 F]FET. Subsequently, 2-[ 18 F]FELP was assessed in vivo and compared with [ 18 F]FET and [ 18 F]FDG in a F98 glioblastoma rat model. 2-[ 18 F]FELP showed improved in vitro characteristics over [ 18 F]Fet, especially when the affinity and specificity for system L is concerned. Based on our results, 2-[ 18 F]FELP is a promising new PET tracer for brain tumor imaging.
In neuro-oncology, the potential of conventional magnetic resonance imaging (MRI) to differentiate neoplastic tissue from non-specific changes induced by treatment may be limited after therapeutic interventions (e.g. radiation therapy, neurosurgical resection, and chemotherapy). The molecular imaging modality positron emission tomography (PET) provides additional information on tumor metabolism, which allows for more accurate diagnostics and therapy response assessment [1] [2] [3] . During the last decades, a variety of molecular targets have been assessed for brain tumor imaging by specific PET tracers. Especially amino acid (AA) based tracers received a lot of attention 2, 4 . In contrast to [ 18 F]fluoro-2-deoxy-d-glucose ([ 18 F]FDG, Fig. 1 ), the uptake of radiolabeled AAs is low in normal gray matter of the brain which results in higher tumor-to-background ratios 5 . A considerable advantage of AA over nucleoside-or choline-based tracers is the ability to pass through the intact blood-brain barrier (BBB) due to the presence of AA transporters. The transport of AA into cells is mediated by specific membrane associated carrier proteins, which are classified into different transporter systems based on criteria such as sodium dependence, substrate specificity, kinetics, etc. 6 . Amongst the currently known AA transporters, system L and system ASC are overexpressed in most tumor tissues, rendering these convenient targets for metabolic imaging of tumor cells [7] [8] [9] . The most widespread 18 Fig. 1 ). Unfortunately, both are not specific for the L-type amino acid transporter 1 (LAT1) and the latter shows uptake in the striatum due to participation in the dopamine synthesis pathway [10] [11] [12] [13] . Most of the amino acid PET tracers, including [ 18 F]FET, still suffer from various levels of physiological background uptake and uptake in non-neoplastic lesions such as acute inflammatory lesions as a result from multiple sclerosis or brain abscesses [14] [15] [16] [17] . An advantage of these non-natural amino acid tracers is the insusceptibility to in vivo metabolism resulting in the absence of radiolabeled metabolites 18 . Different PET and single-photon emission computed tomography (SPECT) tracers based on tyrosine, tryptophan and glutamine have been developed for LAT1 or ASCT2 targeting [19] [20] [21] [22] , of which the most promising results have been reported for 3-fluoro-l-α-methyltyrosine ([ 18 F]FAMT, Fig. 1 ). However, the existing synthetic methods for the preparation of [ 18 F]FAMT suffer from low chemical yields, which limits the availability of this tracer for clinical use 23, 24 . Based on the structure of [ 18 Fig. 1 ) and -fluoropropyl alkylated phenylalanine derivatives, where the former showed appreciable uptake in the 9 L glioma tumor model 25 .
In this study we want to develop a practical synthesis for different phenylalanine derivatives and compare their affinity for the LAT1 transporter. As there are conflicting reports on the preferred stereochemistry of the phenylalanine/tyrosine analogues for the LAT1 transporter [26] [27] [28] , both enantiomers (S) and (R) of ortho- (32 & 33) and meta- (17 & 18) substituted 2-fluoroethyl phenylalanine derivatives ( Fig. 1 ) were synthesized and their K i was determined in LAT1 overexpressing F98 glioblastoma (GB) cells 29 . Previously reported para-substituted derivatives (15 & 16) were included to allow comparison with the novel analogs in our in vitro system. The in vitro uptake of the most promising compound was compared to [ 18 F]FET and its uptake in a rat F98 GB model was evaluated.
Results
Chemistry. Initially, we set out to employ a common starting material (1 & 2, Fig. 2) to gain access to all the different (ortho-, meta-and para-) substituted phenylalanine amino acids. This approach was inspired by recent work of the Baran group, which described arylation of activated glutamate esters with boronic acids under Ni-catalysis 30 . This route could enable access to all different phenylalanine derivatives from a single amino acid precursor.
The synthesis started from suitably protected commercially available l-or d-aspartic acid derivatives (Fig. 2 ). After activation of the side chain carboxylic acid as a N-hydroxytetrachlorophtalimide ester, 1 or 2 was reacted with the corresponding boronic acids (21 (para) or 22 (meta)) to give the substituted phenylalanine derivatives 3-6 in acceptable yields. The preparation of boronic acid derivatives is depicted in Fig. 3 . Commercially available bromo-phenylethanol was protected with TBSCl and subsequently transformed into the corresponding boronic acid by Li/Br exchange and trapping with trimethylborate 31, 32 .
With the boronic acids in hand, cross-coupling was found successful for the synthesis of both para-and metasubstituted derivatives (Fig. 2) . Next, the primary alcohol was unmasked by TBAF in THF, and fluorinated with DAST and deprotected to give rise to the fluorinated amino acids 15-18.
Attempts were made to prepare the ortho-substituted derivatives (32 & 33, Fig. 4 ) with the same strategy, however, this was met with several issues. Firstly, the preparation of TBS-protected ortho-boronic acid was troublesome, as the major product observed was the corresponding oxaborole (data not shown). This could be circumvented by employing the corresponding TIPS-protected alcohol. Next, the cross-coupling reaction with the ortho-substituted boronic acid failed to give appreciable amount of the coupled product, probably due to steric hindrance. This was confirmed by attempting the same reaction with commercially available 2-ethylphenylboronic acid and activated amino acid ester 1 under the same reaction conditions without success. Then, attempts with altered reaction conditions (temperature, catalyst loading and/or catalytic system (bathophenanthroline 30 instead of 4, 4′-di-tert-butyl-2, 2′-dipyridyl, BBBPY)) also did not deliver the desired product (data not shown). Therefore, it was decided to switch to another synthetic route, employing a pre-functionalized phenylalanine starting material ( Fig. 4 ).
This synthetic approach was based on the literature route described for the synthesis of para-substituted phenylalanine amino acids 25, 28 . Commercially available N-Boc-2-bromophenylalanine was protected as its tert-butyl ester with t-butyl 2, 2, 2-trichloroacetimidate (TBTA) and vinylated with a Stille coupling reaction to give 25 and 26. Next, hydroboration introduced the primary alcohol, which was either fluorinated and deprotected to give Radiochemistry. [ 18 F]FET and 2-[ 18 F]FELP were prepared as described below. Enantiomerically pure (ee > 99%) 2-[ 18 F]FELP was synthesized in 90 min with high radiochemical purity (>95% as measured by analytical HPLC and TLC), good yield (10-30% with respect to the starting activity at the end of F18 production, not corrected for decay), and high molar activity (243.7 ± 11.9 GBq/µmol). Chromatograms can be found in the Supplementary Information.
2-[ 18 F]FELP exhibits a logP oct value of −1.16 ± 0.011 which is in accordance with the logP oct value of phenylalanine (logP oct = −1.38) 33 while a logP oct value of −1.48 ± 0.047 was observed for [ 18 F]FET.
Concentration and time dependency using 2-[ 18 F]FELP or [ 18 F]FET.
Since the lowest K i -value was obtained for 2-FELP, the uptake characteristics of this tracer were investigated further and compared with the uptake characteristics of FET (Fig. 6 ). The maximum uptake of [ 18 F]FET, used as a reference, and 2-[ 18 F]FELP was studied in F98 cells. The latter compound seemed more sodium dependent than [ 18 F]FET (44% vs 36% more uptake in presence of Na + ). BCH, a system L and b 0,+ inhibitor, blocked the 2-[ 18 F]FELP or [ 18 F]FET uptake by >99% and 97%, respectively. In the presence of the system A inhibitor, MeAiB, 2-[ 18 F]FELP was inhibited less (51.5% less uptake) 
Discussion
The L-type AA transporter 1 transports aromatic or branched AA that are essential for cellular proliferation and growth. Due to its low expression and distribution in non-pathological cells and upregulation in glioma cells, this AA transporter received a lot of attention as potential target for tumor imaging 1, 13 . Molecular imaging using PET may provide relevant additional information on tumor metabolism and may be useful in case of ambiguous MRI findings following neuro-oncological treatment 35 . In this study, two recently developed fluoroalkyl phenylalanine analogues, 4-FELP and 4-FEDP 25 , together with four new compounds, 2-FELP, 2-FEDP, 3-FELP, 3-FEDP were successfully synthesized and compared in vitro to the reference compound FET, currently used in the clinic. The influence of the stereochemistry on the affinity for the LAT1 transporter was evaluated as there are some conflicting reports in literature. When comparing 123/125 I-labelled 2-iodo-l-phenylalanine and 2-iodo-d-phenylalanine in R1M cells 26 27 reported a higher K i values for d-tyrosine than for 2-I-l-tyrosine. In this study, the in vitro affinity of the d-enantiomers for the LAT1 transporter in F98 GB cells was lower than the affinity of the l-enantiomers, except for the meta-substituted enantiomers. This promiscuity regarding the (stereochemical) substrate preference was observed in a recent publication as well 36 . When considering the K i values of the l-enantiomers, the www.nature.com/scientificreports www.nature.com/scientificreports/ preference of the position of the 2-fluoroethyl substituent on the aromatic ring of phenylalanine was as follows: ortho > meta > para.
Based on earlier studies 36, 37 , it has been shown that meta-substitution appears to be the most tolerant towards substitution. Therefore, it is quite remarkable that the ortho-substituted 2-FELP displays the highest in vitro affinity.
The radiofluorinated 2-[ 18 F]FELP and [ 18 F]FET were successfully prepared on a Synthra RN plus module using identical reaction and purification conditions. The relatively straightforward synthesis method, as described earlier, simplifies the availability for clinical use, which has been an issue for [ 18 F]FAMT 38 .
In the present study, the in vitro influx of 2-[ 18 F]FELP and [ 18 F]FET was characterized in F98 GB cells by means of inhibition experiments, involving the recently identified selective LAT1 inhibitor JPH203, which has structural analogy to tyrosine. Moreover, this compound effectively inhibits the proliferation of various tumor cells injected into nude mice 39 . The uptake of 2-[ 18 F]FELP was considerably lower in presence of the inhibitor JPH203 compared to the uptake of [ 18 F]FET. This indicates that 2-[ 18 F]FELP is predominantly transported by the LAT1 transporter. The results for [ 18 F]FET are in conformity with the study conducted by Langen et al. 40 and the limited inhibition by JPH203 could be explained by LAT2 non-specific uptake, which has been described earlier in F98 cells 41 . As LAT1 overexpression has been correlated with malignant phenotype and proliferation of gliomas, our in-house developed AA could possibly demonstrate value for guiding biopsy, diagnosing primary brain tumor, tumor grading, directing radiotherapy, or even for discriminating between tumor recurrence and radionecrosis post-therapy 42, 43 .
In a second set of in vitro experiments, the K m was determined by means of a concentration dependent assay. The results show a saturable transport consistent with Michaelis Menten kinetics. The K i of 2-[ 18 F]FELP and [ 18 F] FET did not differ significantly from their K m values. The K i value of a competitive inhibitor of a transport process of a substrate is equal to the K m value for transport of the inhibitor by the same process. Therefore, the determination of K i values can be particularly useful if no radioactive labeled compound is available 44 .
Using an in vivo orthotopic tumor model, the uptake of different AA tracers were compared with [ 18 F]FDG uptake characteristics. As described in literature, the AA tracers benefit from a lower background signal, resulting in increased tumor-to-background values 3 . However, no significant differences could be observed between 2-[ 18 F] FELP and [ 18 F]FET. The elevated uptake of both tracers in the GB model could be enhanced by BBB breakdown 45 . We hypothesize that the uptake in low grade glioma, where the BBB is intact and the LAT1 expression is less distinct, would give rise to different time activity curves as seen by Galldiks et al. 46 . Unfortunately, preclinical low grade glioma models are not widely available 47 .
In summary, 2-[ 18 F]FELP has a better affinity and selectivity for the LAT1 transporter compared to [ 18 F]FET, decreasing non-specific tumor uptake. As LAT1 overexpression has been correlated with malignant phenotype and proliferation of gliomas, this new AA tracer could possibly demonstrate value for guiding biopsy, diagnosing primary brain tumor, tumor grading, directing radiotherapy, or even for discriminating between tumor recurrence and radionecrosis after initial therapy 42, 43 .
Conclusion
In this study we synthesized six fluoroalkyl substituted phenylalanine analogues, of which four have not been described before. The affinity of the d-enantiomers for the LAT1 transporter in F98 GB cells was lower than the affinity of the l-enantiomers. 2-FELP exhibits the best affinity for the F98 GB cells. Radiolabeling was performed on a Synthra RN plus module, following the same straightforward method as for [ 18 F]FET. In vitro uptake and inhibition experiments showed that 2-[ 18 F]FELP is predominantly transported by the LAT1 transporter, decreasing non-specific uptake. No significantly different TBR mean , TBR max , SUV mean tumor and SUV max tumor values could be observed in comparison to [ 18 F]FET in the F98 GB rat model. However, in contrast to [ 18 F]FDG PET, higher TBRs were found. Based on our results, 2-[ 18 F]FELP is a promising new PET tracer for glioma or LAT1 imaging.
Methods
General. Reagents and solvents of analytical grade have been obtained from standard commercial sources and were used directly without further purification. Moisture sensitive reactions were performed under an argon atmosphere. Reactions were carried out at ambient temperature, unless specified in the text. For analytical TLC, pre-coated F254 aluminum plates (Machery-Nagel ® ) were employed, which have been visualized by UV and developed with sulfuric acid-anisaldehyde spray/charring. For purification, flash column chromatography was performed using Davisil ® (40-63 µm) silica or a Reveleris X2 (Grace/Büchi) automated Flash unit with prepacked cartridges. Exact mass was analyzed by means of a Waters LCT Premier XE ™ Time of Flight (ToF) mass spectrometer with a standard electrospray (ESI) and modular Lockspray ™ interface. Samples dissolved in an appropriate solvent system and infused in a MeCN/water (1:1) +0.1% formic acid mixture at 100 µL/min. NMR spectra were recorded on a Varian Mercury 300 MHz spectrometer. Chemical shifts (δ) are given in ppm and spectra are referenced to the residual solvent peak signal, with coupling constants (J) expressed in Hz. For 19 F-NMR, signals were referenced to the lock resonance frequency according to IUPAC referencing with CFCl 3 set to 0 ppm. Optical rotations were measured employing a Perkin Elmer 241 Polarimeter.
Chiral HPLC was performed using the specified chiral column (vide infra) from Diacel, 250 × 4.6 mm, particle size 5 µm. Column temperature was 35 °C. Runs were performed isocratically with a mixture of EtOH(abs.)/n-hexane as specified below, with a run length of 30 min at a flow rate of 1 mL/min. 
Experimental procedures & compound characterization data. 1-(tert-butyl)-4-(4, 5, 6, 7-tetrachloro-1,

3-dioxoisoindolin-2-yl)-(tert-butoxycarbonyl)-l-aspartate (1).
Boc-L-aspartic acid 4-tert-butyl ester (0.29 g, 1.0 mmol, 1 eq.) was dissolved in anhydrous DCM (10 mL, 10 mL/ mmol SM). Then, DMAP (0.0012 g, 0.10 mmol, 0.1 eq.) and N-hydroxytetrachlorophthalimide (0.31 g, 1.0 mmol, 1 eq.) were added, followed by DIC (0.175 mL, 1.10 mmol, 1.1 eq.). The resulting suspension was stirred under argon for approximately 2 h. Then, the mixture was filtered and evaporated. Purification by column chromatography (0 → 10% EA/PET) gave 1 (0.34 g, 0.59 mmol) as a white solid in 59% yield. 1 .
According to the procedure described for compound 1; Boc-D-aspartic acid 4-tert-butyl ester (0.87 g, 3.0 mmol) was transformed into 2 (1.2 g, 2.1 mmol) as a white solid in 70% yield. 1 
tert-butyl-(S)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)propanoate (3 -l-type).
1 (0.477 g, 0.833 mmol, 1 eq.) and 21 (0.7 g, 2.5 mmol, 3 eq.) were placed in a 100 mL round bottom flask, equipped with a stir bar. The flask was evacuated and refilled with argon, three times. Then, anhydrous 1, 4-dioxane (33.8 mL, 40 mL/mmol SM) and Et 3 N (1.16 mL, 8.33 mmol, 10 eq.) were added. The resulting mixture was stirred at ambient temperature until a homogeneous solution was obtained (~5 to 10 min). Then, the flask was transferred into a pre-heated oil bath at 75 °C and stirred for another 5 min, after which the catalyst solution (3.4 mL, 4 mL/mmol SM) was added. The resulting solution was stirred at 75 °C overnight. After cooling to ambient temperature, the solvents were removed in vacuo, and the residue taken up in EA/water. The layers were separated, and the water layer extracted twice with EA. The organic layers were combined, dried over Na 2 SO 4 , filtered and evaporated. The residue was purified by column chromatography (0 → 10% EA/PET) to give 3 (0.185 g, 0.386 mmol) as a yellowish oil in 46% yield. 1 30 .
According to the procedure described for 3; 2 (0.41 g, 0.71 mmol) was transformed into 4 (0.31 g, 0.65 mmol) as a colorless oil in 46% yield. 1 
According to the procedure as described for 3; 1 (0.57 g, 1.0 mmol) was transformed into 5 (0.28 g, 0.59 mmol) as a colorless oil in 59% yield. 1 
tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-hydroxyethyl)phenyl)propanoate (6 -d-type).
According to the procedure as described for 3; 2 (0.57 g, 1.0 mmol) was transformed into 6 (0.16 g, 0.34 mmol) as a colorless oil in 34% yield. tert-butyl-(S)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-hydroxyethyl)phenyl)propanoate (7 -l-type 25 .
According to the procedure as described for 7; 4 (0.326 g, 0.7 mmol) was transformed into 8 (0.196 g, 0.536 mmol) as a colorless oil in 77% yield. 1 tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-hydroxyethyl)phenyl)propanoate (9 -l-type) .
According to the procedure as described for 7; 5 (0.547 g, 1.14 mmol) was transformed into 9 (0.29 g, 0.80 mmol) as a colorless oil in 71% yield. 1 www.nature.com/scientificreports www.nature.com/scientificreports/ tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-hydroxyethyl)phenyl)propanoate (10 -d-type) .
According to the procedure as described for 7; 6 (0.26 g, 0.54 mmol) was transformed into 10 (0.15 g, 0.40 mmol) as a colorless oil in 73% yield. 1 
tert-butyl-(S)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-fluoroethyl)phenyl)propanoate (11 -l-type).
7 (0.18 g, 0.49 mmol, 1 eq.) was dissolved in anhydrous DCM (2.5 mL, 10 mL/mmol SM) under argon and cooled in an ice bath at 0 °C. Then, DAST (0.20 mL, 1.5 mmol, 3 eq.) was added dropwise and the resulting solution stirred at ambient temperature for 3-4 h. Then, the mixture was cooled to 0 °C in an ice bath and aq. sat. NaHCO 3 solution was added dropwise. After the gas evolution ceased, the mixture was transferred into a separatory funnel and more sat. aq. NaHCO 3 solution was added. The layers were separated, and the water layer was extracted twice more with DCM. The organic layers were combined, dried over Na 2 SO 4 , filtered and evaporated till dryness. The resulting mixture was purified by column chromatography (0 → 12% EA/PET) to give 11 (0.076 g, 0.21 mmol) as a colorless oil in 42% yield. 1 
tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-fluoroethyl)phenyl)propanoate (12 -d-type).
According to the procedure described for 11; 8 (0.174 g, 0.476 mmol) was transformed into 12 (0.065 g, 0.18 mmol) as a colorless oil in 37% yield. 1 *This peak is in fact a doublet of triplets (F-coupling); however, the peak coincides with the PhCH2CH signal and was not sufficiently resolved for adequate calculation.
www.nature.com/scientificreports www.nature.com/scientificreports/ tert-butyl-(S)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-(tosyloxy)ethyl)phenyl)propanoate (13 -l-type) .
According to the procedure described for 11; 9 (0.235 g, 0.634 mmol) was transformed into 13 (0.117 g, 0.319 mmol) as a colorless oil in 50% yield. 1 
tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-hydroxyethyl)phenyl)propanoate (14 -d-type).
According to the procedure described for 11; 10 (0.146 g, 0.399 mmol) was transformed into 14 (0.042 g, 0.11 mmol) as a colorless oil in 29% yield. 11 (0.076 g, 0.21 mmol) was dissolved in DCM (3.0 mL) after which TFA (3.0 mL) was added. The resulting solution was stirred at ambient temperature for approximately 5 hours, after which it was evaporated till dryness. Next, the residue was co-evaporated with MeOH three times. Then, the residue was dissolved in ~2 mL of MeOH and the pH was adjusted to pH 6-7, with diluted aq. NH 3 www.nature.com/scientificreports www.nature.com/scientificreports/ (R)-2-amino-3-(4-(2-fluoroethyl)phenyl)propanoic acid .
According to the procedure as described for 15; 11 (0.065 g, 0.18 mmol) was transformed into 11 (0.013 g, 0.062 mmol) as a white powder in 35% yield. 1 13 (0.114 g, 0.310 mmol) was dissolved in DCM (3.0 mL) after which TFA (3.0 mL) was added. The resulting solution was stirred at ambient temperature for approximately 5 hours. Then, the mixture was evaporated till dryness. The mixture was co-evaporated with MeOH three times. Then, the residue was neutralized with diluted aq. NH 3 and refrigerated. As no precipitate formed; the mixture was evaporated till dryness and dissolved in water (~5 mL); and the pH adjusted to pH 6. Then, the mixture was purified by RP-flash chromatography (4 g, C-18 column, Büchi). Gradient: 100% water for 1 min, then linear gradient 0 → 20% EtOH/water in 15 min. Product containing fractions were pooled and most of the water was evaporated in vacuo; after which the residue was lyophilized. Then, the white powder was dissolved in water and diluted (~0.5 M) aq. HCl (~0.5 mL) was added and lyophilized again, which gave 17 (0.035 g, 0.14 mmol) as a white powder in 46% yield. 1 14 (0.072 g, 0.20 mmol) was dissolved in DCM (2.0 mL) after which TFA (2.0 mL) was added. The resulting solution was stirred at ambient temperature for approximately 5 hours. Then, the mixture was evaporated till dryness. The mixture was co-evaporated with MeOH three times. Then, the residue was neutralized with diluted aq. NH 3 and refrigerated. As no precipitate formed; the mixture was evaporated till dryness and dissolved in water (~4 mL); and the pH adjusted to pH 6. Then, the mixture was purified by RP-flash chromatography (4 g, C-18 column, Büchi). Gradient: 100% water for 1 min, then linear gradient 0 → 20% EtOH/water in 15 min. Product containing fractions were pooled and most of the water was evaporated in vacuo; after which the residue was lyophilized. Then, the white powder was dissolved in water and diluted (~0.5 M) aq. HOAc (~0.5 mL) was added and lyophilized again, which gave 18 (0.025 g, 0.092 mmol) as a white powder in 46% yield. 1 www.nature.com/scientificreports www.nature.com/scientificreports/ added and stirring continued for 5 min. The organic solvents were removed in vacuo, and DCM was added. The pH was adjusted till pH 1 with 3 M aq. HCl solution, and the layers were separated. The water layer was extracted twice with DCM. The organic layers were combined, dried over Na 2 SO 4 , filtered and evaporated till dryness. The residue was purified by column chromatography (15 → 50% EA/PET), to give 21 (0.71 g, 2.5 mmol) as a colorless oil in 42% yield. 1 H-NMR (300 MHz, CDCl 3 ) δ: 0.00 (s, 6H, 2 × Si-CH 3 ), 0.89 (s, 9H, tBu), 2.91 (t, J = 6.9 Hz, 2H, PhCH 2 ), 3.87 (t, J = 6.9 Hz, 2H, CH 2 (3- (2-((tert-butyldimethylsilyl) oxy)ethyl)phenyl)boronic acid (22) .
According to the procedure as described for 21; 20 (1.9 g, 6.0 mmol) was transformed into 22 (0.925 g, 3.30 mmol) as a colorless oil 55% yield. 1 
tert-butyl (S)−3-(2-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (23 -l-type).
(S)-3-(2-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid (0.69 g, 2.0 mmol, 1eq.) was dissolved in DCM (20 mL, 10 mL/mmol) under argon. Next, tert-butyl 2, 2, 2-trichloroacetimidate (1.3 g, 6.0 mmol, 3 eq.) was added. The resulting solution was stirred at ambient temperature overnight, after which water was added. Then, the layers were separated, and the organic layer was washed with sat. aq. NaHCO 3 solution. The organic layer was dried over Na 2 SO 4 , filtered and evaporated. The residue was pre-adsorbed onto Celite ® and purified by column chromatography (8% EA/PET); which gave 23 (0.72 g, 1.8 mmol) as an oil that solidified upon standing in 90% yield. 1 
tert-butyl (R)-3-(2-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (24 -d-type).
According to the procedure as described for 23; (R)-3-(2-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid (1.7 g, 5.0 mmol) was transformed in to 24 (1.4 g, 3.6 mmol) as a white solid in 72% yield. 1 www.nature.com/scientificreports www.nature.com/scientificreports/ tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2-vinylphenyl)propanoate (25 -l-type) . 23 (0.20 g, 0.50 mmol, 1 eq.), LiCl (0.065 g, 1.5 mmol, 3 eq.) and Pd(Ph 3 P) 2 Cl 2 (0.018 g, 0.025 mmol, 0.05 eq.) were added to a flame-dried round bottom flask under argon. The air was removed and refilled with argon. This procedure was repeated for three times in total. Then, under argon, anhydrous degassed DMF (2.5 mL, 5 mL/ mmol) was added, followed by vinyl-Sn(nBu) 3 (0.19 mL, 0.65 mmol, 1.3 eq.). The resulting mixture was stirred at 70 °C overnight. Then, the mixture was evaporated and re-dissolved in DCM and pre-adsorbed onto Celite ® .
Then, purification by column chromatography (0 → 10% EA/PET) gave 25 (0.089 g, 0.26 mmol) as an oil in 51% yield. 1 
tert-butyl (R)-2-((tert-butoxycarbonyl)amino)-3-(2-vinylphenyl)propanoate (26 -d-type).
According to the procedure described for 25; 24 (0.605 g, 1.5 mmol) was transformed into 26 (0.38 g, 1.0 mmol) as a yellowish oil in 67% yield. 1 
tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2-(2-hydroxyethyl)phenyl)propanoate (27 -l-type).
25 (0.33 g, 0.96 mmol, 1 eq.) was dissolved in anhydrous THF (10 mL, 10 mL/mmol SM) under argon. The resulting solution was cooled to 0 °C in an ice-bath. After 5 min, BH 3 in THF (1 M in THF; 0.96 mL, 0.96 mmol, 1 eq.) was added. Then, the ice-bath was removed, and the resulting solution stirred at ambient temperature for 1 h. Then, NaBO 3 .H 2 O (0.48 g, 4.8 mmol, 5 eq.) was added, followed by water (10 mL, 10 mL/mmol SM). The mixture was vigorously stirred for 2 h. Next, sat. aq. NH 4 Cl was added together with EA. The layers were separated, and the water layer extracted twice more with EA. The organic layers were combined, dried over Na 2 SO 4 , filtered and evaporated till dryness. The residue was purified by column chromatography (0 → 30% EA/PET) to give 27 (0.23 g, 0.64) as a colorless oil in 66% yield. 1 tert-butyl (R)-2-((tert-butoxycarbonyl)amino)-3-(2-(2-hydroxyethyl)phenyl)propanoate (28 -d-type) .
According to the procedure as described for 27; 26 (0.34 g, 0.99 mmol) was transformed into 28 (0.22 g, 0.60 mmol) as a colorless oil in 61% yield. 1 
tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2-(2-fluoroethyl)phenyl)propanoate (29 -l-type).
27 (0.090 g, 0.25 mmol, 1 eq.) was dissolved in anhydrous DCM (2.5 mL, 10 mL/mmol SM) under argon and cooled in an ice bath at 0 °C. Then, DAST (0.10 mL, 0.74 mmol, 3 eq.) was added dropwise and the mixture was stirred at ambient temperature for approximately 3-4 h. Then, the mixture was cooled to 0 °C in an ice bath and aq. sat. NaHCO 3 solution was added dropwise. After the gas evolution ceased, the mixture was transferred into a separatory funnel and more sat. aq. NaHCO 3 solution was added. The layers were separated, and the water layer extracted twice more with DCM. The organic layers were combined, dried over Na 2 SO 4 , filtered and evaporated till dryness. The residue was purified by column chromatography (0 → 12% EA/PET) to give 29 (0.041 g, 0.11 mmol) as a yellowish oil in 45% yield. 1 
tert-butyl (R)-2-((tert-butoxycarbonyl)amino)-3-(2-(2-fluoroethyl)phenyl)propanoate (30 -d-type).
According to the procedure as described for 29; 28 (0.185 g, 0.506 mmol) was transformed into 30 (0.101 g, 0.273 mmol) as a colorless oil in 54% yield. 1 www.nature.com/scientificreports www.nature.com/scientificreports/ 30 (0.090 g, 0.25 mmol) was dissolved in DCM (3.0 mL) after which TFA (3.0 mL) was added. The resulting solution was stirred at ambient temperature for approximately 5 hours, after which it was evaporated till dryness. Next, the residue was co-evaporated with MeOH three times. Then, the residue was dissolved in ~2 mL of MeOH and the pH was adjusted to pH 6-7, with diluted aq. NH 3 solution, after which a white precipitate formed. The mixture was refrigerated overnight, and then the liquid was removed via pipette aspiration. The remaining solid was washed once with a minimal amount of ice-cold MeOH and re-dissolved in MeOH. Then, 1.25 M HCl in MeOH was added and the mixture evaporated till dryness. The residue was dissolved in water and lyophilized, which gave rise to 34 (0.030 g, 0.12 mmol) as a white, amorphous powder in 49% yield. 1 In vitro experiments. General information. The F98 GB cell line was obtained from ATCC and cultivated as described previously 11 . Cells were tested and authenticated by the provider and were cultured for maximum ten weeks after retrieval from liquid nitrogen.
LAT1 expression was determined using flow cytometry. F98 cells (100,000 per well) were surface stained with a monoclonal antibody against LAT1 (PE-conjugated, Santa Cruz biotechnology, Heidelberg, Germany), which acts as a negative control. As described by De Munter et al. 50 , cells were subsequently fixed, permeabilized and submitted for intracellular staining with the same PE conjugated monoclonal antibody against LAT1. Flow cytometric analysis was performed using the LSR II (BD Biosciences).
In vitro experiments were carried out in 24-well-plates (VWR, US), using at least three wells for each data-point. The cells were seeded 24 h prior to the experiment at 200,000 cells/well. Influx of radiolabeled AA was studied in a Na + containing buffer (HEPES+ buffer: pH 7.4; 100 mM NaCl (Sigma Aldrich, Belgium), 2 mM KCl (Sigma Aldrich, Belgium), 1 mM MgCl 2 (VWR, US), 1 mM CaCl 2 (VWR, US), 10 mM Hepes (Sigma Aldrich, Belgium), 5 mM Tris (VWR, US), 1 g/L glucose (VWR, US) and 1 g/L Bovine Serum Albumin (Sigma Aldrich, Belgium)) and/or a Na + free buffer (HEPES-buffer: pH 7.4; 100 mM Choline-Cl (Sigma Aldrich, Belgium), 2 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 10 mM Hepes, 5 mM Tris, 1 g/L glucose and 1 g/L Bovine Serum Albumin). The culture medium was removed, and cells were washed twice with 1 mL HEPES+/HEPES-buffer. Dosing solutions were prepared by supplementing the washing buffer with either 11 kBq [2, 3, 4, 5, 6-3 H]-l-phenylalanine (Perkin Elmer, Massachusetts, USA)/mL or with 37 kBq of the [ 18 F]-labelled AA. The incubation process was terminated by cooling the plates on ice and adding 1 mL 1% BSA ice-cold PBS. Cells were washed twice with 2 mL ice-cold PBS. Subsequently, cells were lysed with 250 µL 0.1 M NaOH (VWR, US) and radioactivity stemming from the [ 18 F]-isotope was counted by subjecting 150 µL of this solution to an automated gamma-counter (Cobra-inspector 5003, Canberra Packard, Meriden, CT, USA). [ 3 H] samples (150 µL) were transferred to a scintillation bottle (Perkin Elmer, Massachusetts, USA) containing 5 mL of scintillation liquid (Ultima Gold, Perking Elmer, Massachusetts, USA) and counted using an automated scintillation counter (TriCarb 2900 TR; Perkin Elmer, Massachusetts, USA). Of each well, 25 µL was subjected to a BCA assay (ThermoFisher Scientific) to determine protein content.
Concentration dependency using [2, 3, 4, 5, H]-l-phenylalanine. Non-linear curve fitting was performed to determine the Michaelis-Menten kinetics using Graphpad Prism v5.01 (Graphpad software, San Diego, CA, USA). These were employed to study the potential inhibition of the AA analogue towards the [ 3 H]-l-Phe/l-Phe couple with varying concentrations (0.01 to 0.5 mM) at 1 min uptake (V 0 conditions). The apparent K m and corresponding K i values were calculated according to the formula:
where [I] is the inhibitor concentration (i.e. the fluorinated AA), K m is the Michaelis-Menten constant of the substrate (i.e. ³H-l-Phe/l-Phe) and K m,app is the apparent value of K m for substrate transport in the presence of the inhibitor.
